Sean Laaman, an analyst from Morgan Stanley, has initiated a new Buy rating on Jazz Pharmaceuticals (JAZZ).
Sean Laaman has given his Buy rating due to a combination of factors including Jazz Pharmaceuticals’ robust growth prospects and strategic focus areas. The company is expected to achieve an 8% increase in product revenue and a 21% growth in Non-GAAP EPS by 2025, driven by its strong presence in neuroscience and oncology. The oxybate franchise is projected to continue its growth trajectory, particularly due to the unmet needs in narcolepsy and idiopathic hypersomnia, which lack effective treatments.
Additionally, the oncology segment, particularly with the drug Ziihera, presents a significant expansion opportunity with its anticipated approval and market penetration in biliary tract cancer and gastroesophageal adenocarcinoma. Jazz’s solid balance sheet further supports its business development initiatives, positioning the company well for future growth. These factors collectively contribute to the positive outlook and the Overweight rating with a price target of $183.
In another report released today, UBS also upgraded the stock to a Buy with a $179.00 price target.
JAZZ’s price has also changed moderately for the past six months – from $107.140 to $136.450, which is a 27.36% increase.